Pharmaceutical MNCs Invest In China’s Diabetes Sector
This article was originally published in PharmAsia News
Executive Summary
The Chinese Diabetes Society recently released its latest survey results prior to World Diabetes Day Nov. 14. According to statistics, the diabetes population in China now stands at 39.8 million, second only to India's 40.9 million. Diabetes morbidity rates from age 20 to 70 years have doubled and quadrupled those of 2001 and 1994, respectively; the number of diabetics in China is expected to hit 59.3 million by 2025. Eyeing the huge market, Novo Nordisk will be building the world's largest insulin factory in Tianjin (PharmAsia News, Nov. 10, 2008). Other MNCs such as Lilly, Sanofi-Aventis and Bayer have plans to expand their investment in China's diabetes sector by enlarging operations, constructing plants or introducing new drugs. (Click here for more - Chinese Language)
You may also be interested in...
Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center
BEIJING - The Danish-headquartered biopharmaceutical outfit Novo Nordisk is building a massive, $400 million insulin plant in the Chinese east coast city of Tianjin to serve diabetes patients across China and Asia, according to company executives and government officials
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.